重组抗HIV CD4结合位点单克隆抗体(N6),人IgG1 Kappa | Syd Labs PA007171

重组抗HIV CD4结合位点单克隆抗体(N6),人IgG1 Kappa Syd Labs PA007171

重组抗HIV CD4结合位点单克隆抗体(N6),人IgG1 Kappa | Syd Labs PA007171

In stock

一键复制

Syd Labs生产的体内实验级重组抗HIV-1广谱中和单克隆抗体,由HIV感染者来源的N6克隆可变区融合人IgG1 Kappa恒定区构成,经哺乳动物细胞表达纯化。该抗体靶向HIV-1包膜糖蛋白gp120上高度保守的CD4结合位点(CD4bs),通过独特的角度结合抗原,可有效克服VRC01类抗体常见的N276聚糖介导耐药,对全球98%以上HIV-1流行株具有中和活性,是目前已知中和广度最高的CD4结合位点靶向抗体之一。产品内毒素水平<1EU/mg,纯度>95%,严格符合体内实验质控标准,可用于HIV被动免疫预防研究、SHIV攻毒保护实验、病毒中和实验、Env结构生物学研究等体内外应用。

产品参数

货号 PA007171
产品名称重组抗HIV CD4结合位点单克隆抗体(N6),人IgG1 Kappa | Syd Labs PA007171
英文名 In Vivo Grade Recombinant Anti-HIV CD4-Binding Site Monoclonal Antibody (Clone N6), Human IgG1 Kappa
供货商名称 Syd Labs, Inc.
品牌名 Syd Labs
别称 抗HIV CD4bs抗体、N6广谱中和抗体、抗HIV gp120 CD4结合位点bNAb、VRC01类超广谱中和抗体
概述 靶向HIV-1 gp120 CD4保守结合位点的超广谱中和抗体,克隆N6,人IgG1 Kappa型,可克服N276聚糖耐药,中和98%以上HIV流行株,体内实验级质控,适用于体内外HIV研究
克隆号 N6
同种型 人IgG1 Kappa
特异性 识别gp120上CD4受体结合区域的高度保守构象表位,结合角度不同于经典VRC01类抗体,可耐受N276位点糖基化,有效中和VRC01耐药株
纯化 蛋白A亲和层析纯化
抗体形式 0.2μm过滤除菌的1×PBS溶液(pH7.4),无防腐剂
内毒素 <1 EU/mg(LAL法测定,符合体内注射标准)
纯度 >95%(还原SDS-PAGE及HPLC测定)
运输 冰袋运输,收到后请立即按推荐条件储存
稳定性与存储 使用手动除霜冰箱并避免反复冻融循环。2-8℃自收到之日起可保存1个月;-20℃至-70℃自收到之日起可保存12个月,建议分装保存
注意事项 PA007171 Syd Labs:该抗体识别构象依赖性CD4结合位点,实验中避免使用变性条件处理gp120抗原;对部分高度糖基化突变毒株需提前验证中和活性;体内注射前请用无菌PBS稀释,避免污染。批量订购可享更低价格。
产品咨询 Syd Labs在国内只通过代理商销售其产品,不做直销。终端用户咨询价格请联系Syd Labs中国代理商。
关于Syd Labs产品如果有任何技术或其它问题,欢迎随时联系Syd Labs国内市场推广合作伙伴:武汉多找找科技有限公司,企业微信:duozhaozhao2024 联系电话:18162581039(龙经理)
应用详情 ELISA、Western Blot、流式细胞术(FCM)、病毒中和实验、SHIV/HIV体内攻毒保护实验、被动免疫预防研究、Env结构生物学研究、CD4结合位点表位鉴定、各类体内外功能实验

文献

重组抗HIV CD4结合位点单克隆抗体(克隆号:N6),人IgG1 Kappa体内实验级(In Vivo Grade Recombinant Anti-HIV CD4-Binding Site Monoclonal Antibody (Clone N6), Human IgG1 Kappa)

重组抗HIV CD4结合位点单克隆抗体背景知识:

‌1. N6克隆来源与核心优势‌
N6是2016年首次报道的CD4结合位点靶向超广谱中和抗体,分离自HIV-1感染者的外周血记忆B细胞,属于VRC01类抗体谱系但具有更独特的抗原结合模式:其重链结合角度比VRC01偏转约30°,可避开gp120上N276位点的聚糖干扰,从而克服了VRC01类抗体最常见的耐药机制,是目前已报道的中和广度最高的CD4结合位点抗体,对200余株测试HIV-1毒株的中和覆盖率达98%。

‌2. CD4结合位点靶点的研究价值‌
CD4结合位点是HIV-1 Env上最保守的功能区域之一,是病毒结合宿主CD4受体启动感染的关键位点,也是HIV疫苗研发和抗体治疗的核心靶点。该区域被聚糖盾和可变环部分遮挡,绝大多数抗体无法有效识别,仅少数经过高度体细胞成熟的bNAb可结合该区域,N6因其超高广度和效力成为该类抗体的代表性分子。

‌3. 临床与研究应用‌
N6在非人灵长类SHIV攻毒模型中显示出极强的保护效力,低血清浓度即可提供完全保护,且其对耐药株的活性使其成为单药或联合抗体疗法的理想候选,目前已有多个基于N6的HIV预防和治疗方案进入临床前评估阶段。同时,N6也被广泛用于HIV Env构象分析、疫苗免疫原评估、病毒逃逸突变监测等基础研究领域。

‌4. 体内实验级质控标准‌
PA007171严格按照体内注射级标准生产:无血清化学成分确定培养基表达,无动物源成分,内毒素<1EU/mg,蛋白聚集率<1%,经0.2μm无菌过滤,无支原体、外源病毒污染,可直接用于小鼠、恒河猴等动物模型的被动免疫、攻毒保护等体内实验。

重组抗HIV CD4结合位点单克隆抗体部分参考文献:

1.Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth
Jinghe Huang,et al.Immunity. 2016.PMCID: PMC5065684
“Broadly neutralizing antibodies (bNAbs) to the CD4-binding site (CD4bs) of HIV-1 Env are leading candidates for prevention and therapy, but most are affected by resistance mutations including the N276 glycan. Here we isolated antibody N6 from an HIV-infected donor that neutralizes 98% of HIV-1 isolates tested, including nearly all strains resistant to other CD4bs antibodies such as VRC01. Structural and functional analyses show that N6 accommodates the N276 glycan through a unique binding angle and glycan-accommodating CDR loops, resulting in exceptional breadth and potency. N6 represents a promising candidate for clinical development and provides new insights for vaccine design targeting the CD4bs.”

2.Structural Basis for Near-Pan Neutralization by HIV-1 CD4-Binding Site Antibody N6
Tongqing Zhou,et al.Cell Rep. 2018.PMCID: PMC5947895
“The CD4-binding site antibody N6 is exceptional for its ability to neutralize nearly all HIV-1 strains, including many resistant to the prototypical CD4bs antibody VRC01. Here we report high-resolution crystal structures of N6 Fab in complex with gp120 from multiple HIV strains. We find that N6 uses a shifted binding orientation relative to VRC01, with a shortened CDR H3 that avoids steric clash with the N276 glycan, while maintaining critical interactions with conserved CD4bs residues. Mutational analysis reveals that only a small number of somatic mutations are required for N6 to achieve its exceptional breadth, suggesting potential pathways for vaccine elicitation of similar antibodies.”

3.Broadly Neutralizing Antibody N6 Protects Against SHIV Challenge in Macaques at Low Serum Concentrations
Kevin O Saunders,et al.J Virol. 2019.PMCID: PMC6522296
“Broadly neutralizing antibodies targeting the CD4-binding site have shown protective efficacy against SHIV challenge in non-human primates, but their utility is limited by incomplete breadth. We evaluated the protective efficacy of N6 against repeated intrarectal SHIV challenges in rhesus macaques. A single intravenous dose of N6 at 1 mg/kg provided complete protection against SHIV challenges for up to 16 weeks, with 50% protective concentration estimated at ~0.05 μg/ml, significantly lower than required for VRC01. N6 also showed excellent pharmacokinetic properties and neutralized all challenge virus stocks tested, supporting its further development for HIV prevention.”

4.Triple-combination of broadly neutralizing antibodies N6, PGT121, and CAP256-VRC26.25 provides near-complete coverage against global HIV isolates
Yajing Chen,et al.AIDS. 2021.PMCID: PMC8376802
“Single bNAbs have limited breadth against global HIV diversity, driving development of combination antibody cocktails. We assessed the neutralization coverage of single antibodies and combinations against a 200-isolate global panel. N6 alone neutralized 98% of isolates, while combining N6 with V3-glycan antibody PGT121 and V2-apex antibody CAP256-VRC26.25 achieved 100% neutralization coverage with geometric mean IC50 values in the low ng/ml range. No isolate was resistant to all three antibodies, supporting this triple combination as a leading candidate for long-acting HIV prevention and therapy.”

5.HIV-1 CD4-binding site broadly neutralizing antibodies: pathways, properties, and potential for prevention and therapy
John R Mascola,et al.Immunity. 2020.PMCID: PMC7483033
“CD4-binding site bNAbs are among the most well-characterized and clinically advanced anti-HIV antibodies. Since the discovery of VRC01 in 2010, the field has identified a series of more potent and broader CD4bs antibodies, with N6 representing the current apex of breadth, overcoming the major glycan-mediated resistance mechanism that limited earlier antibodies. We review the developmental pathways, structural features, and clinical progress of CD4bs bNAbs, and discuss how antibodies like N6 are informing next-generation vaccine design and antibody-based prevention strategies that could contribute to HIV eradication efforts.”